You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 5,470,567

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,470,567

Title:	Synergistic skin depigmentation composition
Abstract:	There is disclosed a synergistic composition and process for skin depigmentation with reduced irritation which does not employ a corticosteroid and which employs a substituted oxybenzene and a retinoid.
Inventor(s):	Nair; Xina (E. Amherst, NY), Tramposch; Kenneth M. (Williamsville, NY)
Assignee:	Bristol Myers Squibb Company (New York, NY)
Application Number:	08/141,503
Patent Claims:	1. A synergistic composition for skin depigmentation free of corticosteroid comprising: (a) 4-hydroxyanisole in an amount from about 0.1% to about 2% by weight; (b) a retinoid selected from the group consisting of all-trans retinoic acid in an amount from about 0.001% to about 0.1% by weight, (N-acetyl-4-aminophenyl) retinoate in an amount from about 0.001% to about 0.01%, and 11-cis, 13-cis-12-hydroxymethyl retinoic acid .delta.-lactone in an amount from about 0.001% to about 0.1% by weight; and (c) a dermatologically acceptable carrier. 2. The composition of claim 1 comprising from about 1% to about 2% of 4-hydroxyanisole and from about 0.01% to about 0.1% of all-trans retinoic acid. 3. The composition of claim 1 comprising from about 1% to about 2% of 4-hydroxyanisole and from about 0.001% to about 0.01% of (N-acetyl-4-aminophenyl) retinoate. 4. The composition of claim 1 comprising from about 1% to about 2% of 4-hydroxyanisole and from about 0.01% to about 0.1% of 11-cis, 13-cis-12-hydroxymethyl retinoic acid .delta.-lactone. 5. A method for skin depigmentation which comprises topically applying to the skin a synergistic composition free of corticosteroid which comprises: (a) 4-hydroxyanisole in an amount from about 0.1% to about 2% by weight; (b) a retinoid selected from the group consisting of all-trans retinoic acid in an amount from about 0.001% to about 0.1% by weight, (N-acetyl-4-amino-phenyl) retinoate in an amount from about 0.001% to about 0.01% by weight and 11-cis, 13-cis-12-hydroxymethyl retinoic acid .delta.-lactone in an amount from about 0.001% to about 0.1% by weight; and (c) a dermatologically acceptable carrier. 6. The method of claim 5 wherein the composition comprises from about 1% to about 2% of 4-hydroxyanisole and from about 0.01% to about 0.1% of all-trans retinoic acid. 7. The method of claim 5 wherein the composition comprises from about 1% to about 2% of 4-hydroxyanisole and from about 0.001% to about 0.01% of (N-acetyl-4-aminophenyl) retinoate. 8. The method of claim 5 wherein the composition comprises from about 1% to about 2% of 4-hydroxyanisole and from about 0.01% to about 0.1% of 11-cis, 13-cis-12-hydroxymethyl retinoic acid .delta.-lactone.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.